Intra-Cellular Therapies, Inc.

Related records

Trials (44)

• A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
• A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
• A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
• A Trial to Assess the Antipsychotic Efficacy of ITI-007
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• Caplyta in Borderline Personality Disorder
• Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
• Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
• Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
• ITI-007 (Lumateperone Tosylate) for Schizophrenia
• ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
• Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
• Lumateperone for Late-Life Depression
• Lumateperone for the Prevention of Relapse in Patients With Schizophrenia
• Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
• Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia